as u s pat no 7 956 173 commonly owned and co pending u s patent application ser no 12 258 383 now issued as u s pat no 8 026 342 and commonly owned and co pending u s patent application ser no 11 925 173 now issued as u s pat no 8 614 103 as compared to the murine anti s1p antibody from which lt1009 was derived the humanized form exhibits an s1p binding affinity in the picomolar range as well as and superior stability and in vivo efficacy because isonep has demonstrated anti inflammatory anti fibrotic and anti angiogenic activity the safety and efficacy of isonep were evaluated in a phase i clinical trial in patients with wet amd the therapeutic methods and compositions of the invention act by changing the effective concentration i e the absolute relative effective and or available concentration and or activities of certain undesired bioactive lipids e g s1p lowering the effective concentration of the bioactive lipid may be said to u201c neutralize u201d the target lipid or its undesired effects including downstream effects here u201c undesired u201d refers to a bioactive lipid that is unwanted due to its involvement in a disease process for example as a signaling molecule or to an unwanted amount of a bioactive lipid which contributes to disease when present in excess it is believed that neutralizing s1p will be efficacious in patients with cnv wet amd pigment epithelial detachment ped and other ocular diseases and conditions characterized wholly or in part by inflammation unwanted angiogenesis and or fibrosis as with.